Palvella Therapeutics, Inc. (PVLA:NASDAQ) closed at $125.10 on October 23, 2026, down 1.02% on the day. The stock trades 22.5% below its 52-week high of $161.38 and 81.4% above its 52-week low of $68.96. Over the past year, it gained 71.4%. Palvella Therapeutics, Inc. is part of the Health Care sector.
In 252 trading sessions since October 23, 2025, PVLA closed higher on 125 days (50%). Its best day was February 24, 2026 (+37.08%) and its worst was July 20, 2026 (-21.04%). The stock moved 10% or more in a single session 11 times. It opened at least 5% above the previous day's high 3 times.
Pieris Pharmaceuticals Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of the Anticalin class of biotherapeutics. Anticalin proteins are engineered versions of lipocalins, human proteins that naturally bind, store and transport a wide spectrum of molecules. The company with the help of technology creates differentiated drugs such as PRS-080, PRS-060, PRS-343, and PRS-332 that can help patients suffering from cancer, severe asthma, anemia, and other medical conditions with a high unmet medical need. Geographically, all the operation of the firm functions through the region of the United States.
Find more stocks like PVLA with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.